About Glioblastoma Heterogeneity
Glioblastoma Heterogeneity
About this Collection
This collection is now closed to submissions.
Brain tumours remain one of the most difficult groups of malignancies to treat, with glioblastoma (GBM) being the most common and aggressive form. GBM has a poor prognosis with a mean survival period of 15 months, highlighting a desperate need for new therapies and treatment options to improve clinical outcomes for patients.
Advances in the treatment of GBM has been confounded by tumour heterogeneity which arises as selection pressures in the tumour microenvironment drive genomic and other biological variations. This heterogeneity confers GBM tumours with plasticity to respond to different environmental pressures which contributes to drug resistance and tumour recurrence after therapy as tumour cell populations modify their gene expression and metabolic programs to survive. As such therapies have variable efficiency across patient cohorts and even across different cell populations within the same patient’s tumour. The translation of findings from the bench to the clinic requires tools and techniques to assay the complexity of the microenvironment and a more patient specific viewpoint towards treatment.
We seek to bring together a collection of research articles, method papers, reviews, commentaries and data notes to share the latest research into GBM heterogeneity and the tumour microenvironment, with a focus on new technologies, methods and techniques advancing the field.
Keywords: glioblastoma; tumour heterogeneity; tumour microenvironment; cancer metabolism; cancer mechanobiology; cancer vasculature; cancer stem cells; cancer transcriptomics; spatial technologies; new targets; drug-screenings; artificial intelligence; 3D cell culture models; bioengineering
This collection is now closed.
This collection is part of the Cell & Molecular Biology Gateway.
Any questions about this collection? Please get in contact directly with research@f1000.com.
Brain tumours remain one of the most difficult groups of malignancies to treat, with glioblastoma (GBM) being the most common and aggressive form. GBM has a poor prognosis with a mean survival period of 15 months, highlighting a desperate need for new therapies and treatment options to improve clinical outcomes for patients.
Advances in the treatment of GBM has been confounded by tumour heterogeneity which arises as selection pressures in the tumour microenvironment drive genomic and other biological variations. This heterogeneity confers GBM tumours with plasticity to respond to different environmental pressures which contributes to drug resistance and tumour recurrence after therapy as tumour cell populations modify their gene expression and metabolic programs to survive. As such therapies have variable efficiency across patient cohorts and even across different cell populations within the same patient’s tumour. The translation of findings from the bench to the clinic requires tools and techniques to assay the complexity of the microenvironment and a more patient specific viewpoint towards treatment.
We seek to bring together a collection of research articles, method papers, reviews, commentaries and data notes to share the latest research into GBM heterogeneity and the tumour microenvironment, with a focus on new technologies, methods and techniques advancing the field.
Keywords: glioblastoma; tumour heterogeneity; tumour microenvironment; cancer metabolism; cancer mechanobiology; cancer vasculature; cancer stem cells; cancer transcriptomics; spatial technologies; new targets; drug-screenings; artificial intelligence; 3D cell culture models; bioengineering
This collection is now closed.
This collection is part of the Cell & Molecular Biology Gateway.
Any questions about this collection? Please get in contact directly with research@f1000.com.
Collection Advisors
-
Guillermo Gomez
View Profile -
Chloe Shard
View Profile
